Abstract: The present invention relates to an amyloid ? peptide analogues comprising an amino acid sequence or a peptidomimetic thereof, wherein the sequence (i) forms a loop, (ii) has at least 66% identity to the amino acid sequence of native A? peptide or a portion thereof, (iii) comprises at least 6 contiguous amino acid residues and (iv) has at least 2 non-contiguous amino acid residues which are covalently linked with each other, oligomers comprising a plurality of said amyloid ? peptide analogues, processes for preparing the amyloid ? peptide analogues or oligomers, compositions comprising the amyloid ? peptide analogues or oligomers, and uses of the amyloid ? peptide analogues or oligomers such as their use for treating or preventing an amyloidosis (e.g. by active immunization), for diagnosing an amyloidosis, and for providing agents that are capable of binding to the amyloid ? peptide analogues or oligomers.

Abstract: The present disclosure describes a biologically active modified urokinase and high resolution crystalline forms of modified urokinase. Polynucleotides which encode modified urokinase and methods for making modified urokinase are also disclosed.